December 10-13, 2022; New Orleans, Louisiana
Long-term follow-up did not show improved survival with lenalidomide/dexamethasone induction, reduced-intensity melphalan, and transplant followed by lenalidomide maintenance vs continuous lenalidomide/dexamethasone in patients 60-75 years of age with newly diagnosed multiple myeloma.